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Introduction
Th  e introduction of TNF-blocking biologic drugs has 
constituted the greatest advance in the treatment of 
spondyloarthritis (SpA) over the past 50 years. At last, 
SpA – so long the Cinderella compared with rheumatoid 
arthritis – has entered the limelight with many patients 
previously untreated or unrecognised seeking the new 
magic bullet. Th   e availability of eﬀ  ective anti-TNF treat-
ment has exposed the personal and societal economics of 
treating and failing to treat these disorders as well as their 
impact on individual lives.
New treatments have complemented advances in under-
standing of pathological changes in SpA, especially the key 
role played by enthesitis in peripheral and spinal lesions. 
New imaging techniques have made it clear that anky-
losing spondylitis (AS), although identiﬁ  ed histori  cally by 
classic radiographic change, is a continuum from a pre-
radiographic phase to a radiographic phase – the whole 
continuum being appropriately referred to as Axial SpA 
[1]. During the radiographic phase, skeletal lesions are 
probably irreversible and may progress independently of 
ongoing inﬂ  ammation; conversely, the opportunities for 
prevention or reduction of skeletal damage may be found 
during the pre-radiographic phase, although recog  nition 
of disease at this time is problematic. At this early stage, 
acute inﬂ   ammatory lesions may be wide  spread and 
ﬂ  uctuating throughout the spine [2,3]; the transformation 
of these acute lesions to more chronic fatty bone and 
entheseal lesions may be what promotes the formation of 
new bone and hence ankylosis. It is therefore likely that 
treatment of spinal inﬂ   ammation and symptoms may 
come to be divorced from therapeutic prevention of 
skeletal damage.
Limitations of conventional approaches to 
treatment
Th   e crucial importance of new and emerging therapies in 
the ﬁ  eld of SpA is best seen in the context of the short-
comings of current conventional treatment approaches. 
Undoubtedly nonsteroidal anti-inﬂ  ammatory  drugs 
reduce symptoms of AS and their continuous use may 
reduce the rate of ankylosis [4], but the mechanism of 
such an eﬀ   ect is not clear. Conventional disease-
modifying anti-rheumatoid drugs (DMARDs), however, 
exert neither symptomatic nor disease-modifying eﬀ  ects 
on the spine – and although used for treatment of 
peripheral joint disease, evidence of eﬃ   cacy is limited. 
Th   e evidence for eﬃ   cacy of various medications on SpA 
has been summarised [5] and Assessment of Spondylo-
arthritis International Society (ASAS)/European League 
Against Rheumatism (EULAR) treatment recom  menda-
tions have been made [6].
In spite of evidence linking infection with the patho-
genesis of both axial and peripheral SpA, notably reactive 
arthritis, the potential eﬃ   cacy of antimicrobial therapy 
on the course of SpA remains uncertain. Th   e evidence of 
eﬃ   cacy of antimicrobial treatment of reactive arthritis 
has been reviewed elsewhere [7]. In both peripheral and 
axial SpA, therefore, there is a strong desire for more 
eﬀ   ective symptom-controlling agents and a need for 
drugs that truly modify disease outcome.
Abstract
TNF blockade therapy has substantially advanced 
the treatment of peripheral spondyloarthritides but 
revolutionised the treatment of severe ankylosing 
spondylitis. The capacity of biologic treatment to 
improve dramatically symptoms and quality of life in 
patients with spinal disease is undoubted, although 
important questions remain. Notable amongst these 
are concerns about skeletal disease modifi  cation and 
the true balance between costs and eff  ectiveness. 
Guidelines for the biologic treatment of ankylosing 
spondylitis and psoriatic arthritis have been introduced 
in North America and Europe with considerable 
consensus. However, the absence of clear criteria 
for the diagnosis of early disease leaves the issue of 
biologic treatment of ankylosing spondylitis at the pre-
radiographic stage unresolved. Newer biologic agents 
are entering the fi  eld, although superiority over TNF 
blockers will be diffi   cult to demonstrate.
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Recent studies have done much to identify and measure 
the outcomes of treatment of SpA for the purposes of 
both research and clinical practice. Th   e development of 
valid, reproducible and objective assessments of axial 
disease (spondylitis) has been especially diﬃ   cult, although 
valuable instruments have been devised by several groups – 
notably from Bath in the UK and by the ASAS, hence use 
of the preﬁ  xes Bath and ASAS. Further development of 
truly objective measures remains desirable. Th  e key 
measures most used in spondyloarthritides are described 
in the ASAS handbook for assessment in SpA and 
elsewhere [8,9]. Table 1 presents a summary of the key 
outcomes for assessment of axial disease in AS.
Biologic treatment of spondyloarthritides
Th  e key therapeutic development in SpA is the intro-
duction of TNF blockade therapy. Other agents, 
including orally administered drugs, may enter the ﬁ  eld 
in the near future but the present review focuses on the 
biologic agents studied and used thus far in the treatment 
of SpA. Separate consideration of treatment of axial and 
peripheral disease is appropriate.
Axial spondyloarthritis
Th   e biologic agents studied and used in the treatment of 
axial SpA are presented in Table 2.
Th   e TNF blockers have become well established in the 
management of SpA and key aspects of their use and 
eﬃ   cacy are summarised below. Comparability between 
studies is hampered by use of a range of diﬀ  erent 
measures and by variations in study design, although 
there are clear anti-TNF class eﬀ  ects with relatively small 
diﬀ  erences in eﬃ   cacy between agents.
Axial disease activity
Reductions in evidence of disease activity – notably pain, 
stiﬀ  ness and fatigue – are achieved by all TNF blocking 
agents studied; comparable responses in the ASAS 20, 
ASAS 40 and ASAS 5/6 and the Bath  Ankylosing 
Table 1. Key outcome measures in common use for assessment of axial disease in ankylosing spondylitis
Outcome Instrument  Main  components  Reference
Disease activity  BASDAI  Self-administered VAS questionnaire: fatigue, axial pain, peripheral joint pain, tenderness,   [99]
   stiff  ness
  ASAS 20, 40, 70  Percentage improvement in three out of four domains: patient global, pain, function and   [100,101]
   infl   ammation
  ASAS 5/6  >20% improvement in all four ASAS domains + one of CRP or metrology  [101]
  Partial remission  <20% activity in all four ASAS domains  [100]
  ASDAS Includes  CRP  [102]
Physical function  BASFI  Self-administered VAS questionnaire: 10 questions about day-to-day tasks  [103]
  Dougados index  Self-administered VAS questionnaire: 20 questions about day-to-day tasks  [104]
  HAQ-S  Self-administered questionnaire scoring diffi   culty of 25 day-to-day tasks  [105]
Metrology  BASMI  Five clinical measurements: cervical rotation, tragus to wall distance, lateral lumbar fl  exion,   [106]
    modifi  ed Schober’s, intermalleolar distance
  EDASMI  Four clinical measurements: cervical rotation, lateral lumbar fl  exion, chest expansion, and   [107]
    internal rotation of the hip
Spine X-ray score  mSASSS  Disease of anterior vertebral corners on a lateral cervical and lumbar radiograph   [108]
Spine MRI score  Berlin Score  Vertebral junction disease by quantifying bone marrow oedema   [109]
  ASspiMRI-a   Vertebral junction disease by quantifying bone marrow oedema and erosions  [110]
  SPARCC Index  Vertebral junction disease by quantifying bone marrow oedema   [111]
Work  AS-WIS  A simple 20-item questionnaire to measure work instability in AS  [112]
  WPAI-SHP  Quantitative measure of reduced productivity, both at work and during nonwork activities  [113]
  Questionnaire  
Health-related quality of life  ASQoL  Addresses symptoms, function and disease-related concern  [114]
  SF-36  Physical and mental health assessment  [115]
AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing 
Spondylitis Quality of Life; ASspiMRI, Ankylosing Spondylitis Spine MRI score; AS-WIS, Ankylosing Spondylitis Work Instability Scale; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; 
EDASMI, Edmonton Ankylosing Spondylitis Metrology Index; HAQ, Health Assessment Questionnaire; MRI, magnetic resonance imaging; mSASSS, Modifi  ed Stoke 
Ankylosing Spondylitis Spinal Score; SF-36, Short-form 36; SPARCC, Spondyloarthritis Research Consortium of Canada; VAS, visual analogue scale; WPAI-SHP, Work 
Productivity and Activity Impairment-Specifi  c Health Problem Questionnaire.
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been achieved by adalimumab, etanercept and inﬂ  iximab. 
Th  ese responses are achieved as early as 2 weeks after 
treatment [10]. It is clear that a BASDAI 50 response is 
maintained at 1 year by 47 to 58% of patients and an 
ASAS 20 response at 2 years by 65 to 83% of patients. 
Partial remission is maintained by one-third of patients 
at 2 and 3 years [11-13]. Reductions in the BASDAI and 
achievement of ASAS criteria based on intention to treat 
data are summarised from representative studies in 
Table 3.
Preliminary data are available for several other bio-
logical agents. Eﬃ   cacy of golimumab, a fully humanised 
TNF inhibitor, is comparable with other TNF inhibitors 
over the short term [14] but longer-term experience is 
awaited. Rituximab, in a 24-week phase II trial (see 
Table 2), was as eﬀ  ective as TNF inhibitors in anti-TNF-
naïve patients with active AS but appeared ineﬀ  ective in 
patients who had failed such treatment [15]. Limited data 
on use of anakinra have suggested less signiﬁ  cant beneﬁ  ts 
in the treatment of AS [16,17], and reports of the use of 
other biologic agents are anecdotal.
Magnetic resonance imaging (MRI), using the 
Ankylosing Spondylitis Spine MRI score, has established 
that the acute changes of spinal inﬂ  ammation respond 
well to anti-TNFα therapy. A reduction in MRI signs of 
spinal inﬂ  ammation of the order of 40 to 50% was seen 
after 3 months of treatment with inﬂ   iximab, and this 
reduction persisted after 2 years. At this point, however, 
there was some residual spinal inﬂ  ammation in approxi-
mately 80% of patients [18]. Signiﬁ  cant improvement in 
the Ankylosing Spondylitis Spine MRI score with 
etanercept treatment has been seen as early as 12 weeks, 
and this beneﬁ  t was maintained at 6 months [19]. Similar 
improvement in spinal and sacroiliac inﬂ  ammation was 
seen in adalimumab-treated patients using the Spondylo-
arthritis Research Consortium of Canada scoring method. 
Th  is  beneﬁ  t was maintained at week 52 of therapy [20].
Both inﬂ  iximab [21] and adalimumab [22] have been 
shown to be eﬀ   ective at controlling symptoms and 
ameliorating MRI spinal changes in early disease (axial 
SpA), although any long-term disease-modifying eﬀ  ect 
has yet to be observed. Th   e likelihood of clinical response 
to anti-TNF has been found to be greater in patients with 
shorter disease duration [23].
Function, work and productivity
Improvement in function, as measured by the Bath 
Ankylosing Spondylitis Functional Index, is seen as early 
as 2 to 12 weeks after initiation of TNF blockade therapy 
[10,24,25] and is maintained for at least 3 to 5 years 
[11,12].
Th  is functional improvement is rapidly reversed on 
early discontinuation of treatment. Greater functional 
improvement is more likely to occur in those patients 
with early disease; these data should be seen in the 
context of the natural progression of untreated or con-
ventionally treated disease, in which one estimate 
indicates natural progression of functional deterioration 
at 0.05 Bath Ankylosing Spondylitis Functional Index 
units per year [26].
Although separately measured, a close associate of 
function is the capacity for work and productivity. AS is 
associated with substantial work disability and loss of 
work productivity  [27]. Work capacity also correlates 
with quality-of-life measures such as the Ankylosing 
Spondylitis Quality of Life [28]. Self-reported improve-
ment in work capacity has been noted as early as 
24 weeks after anti-TNF therapy [29], and return to work 
of some patients has been reported after a mean of 
18  months of therapy [30]. Th  is clearly has important 
impli  cations for individual income, self-esteem and 
family welfare in addition to assessment of the cost-
eﬀ  ectiveness of these agents.
Health-related quality of life
Treatment with each of the available anti-TNF agents has 
been associated with signiﬁ   cant improvement in the 
physical component of the Short-form 36 (SF-36) score. 
Improvement occurs between 6 and 12 weeks [10,24] and 
is maintained in long-term trials [11]. Nonsigniﬁ  cant 
improvements in the mental component scores also 
Table 2. Biological agents in ankylosing spondylitis
         Published  randomised
Name  Biologic class  Half-life  Administration  Frequency  control trial data
Infl  iximab  Chimeric TNF inhibitor  8 to 9 days  Intravenous   Every 6 to 8 weeks  5 years [11]
Etanercept  Fusion protein TNF inhibitor  70 hours  Subcutaneous  Twice a week or weekly  5 years [92]
Adalimumab  Fully human TNF inhibitor  2 weeks  Subcutaneous  Fortnightly  3 years [38]
Golimumab  Fully human TNF inhibitor  2 weeks  Subcutaneous  Every 4 weeks  24 weeks [14]
Rituximab  Anti-CD20 (anti-β cell)   3 weeks  Intravenous   Two doses  24 weeks [15]
Ustekinumab  Fully human IL-12 and IL-23 inhibitor  3 weeks  Subcutaneous  Every 4 weeks in psoriatic arthritis  None
Anakinra  IL-1 inhibitor  4 to 6 hours  Subcutaneous  Daily  24 weeks [17]
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signiﬁ   cant improvement in Ankylosing Spondylitis 
Quality of Life, which is maintained in long-term trials 
[13].
Fatigue and sleep disturbance are important features of 
active AS. All anti-TNF agents are associated with 
improve  ment in fatigue, as reﬂ  ected by reduction in the 
BASDAI fatigue scale, and improvement of sleep, using 
the Jenkins sleep scale, has been reported with 
golimumab treatment [14].
Spinal movements
Improvement in metrology has been modest in most 
studies of TNF blockade therapy, reﬂ   ecting both the 
extent of irreversible disease and insensitivity of this 
measure. Some improvement in the Bath Ankylosing 
Spondylitis Metrology Index (BASMI) score may be seen 
as early as 2 to 12 weeks [10,24,25], and this is sustained 
in most patients. It is clear, however, that maintenance of 
improvement in spinal mobility requires sustained 
regular mobilisation exercises.
Disease modifi  cation of radiographic disease progression
Assessing disease progression in axial SpA is an imperfect 
art. Methods for scoring disease progression are 
proble  matic [31]. Th  e  modiﬁ   ed Stoke Ankylosing 
Spondylitis Spine Score [32]  is currently the most 
sensitive to change of the methods and is therefore the 
radiographic method of choice for detecting radiographic 
progression [33]. Reliance on anterior changes at two 
segments of the spine and exclusion of the posterior 
elements and thoracic segment are, however, undoubted 
limitations. Assessment of disease progression has also 
been hampered by lack of long-term follow-up of 
randomised controls on both ethical and practical 
grounds. Treatment groups have therefore been 
compared with historical control groups such as the 
Outcome Assess  ments in Ankylosing Spondylitis 
International Study cohort, in which patients received 
nonsteroidal anti-inﬂ   ammatory drugs, analgesics and 
regular exercise therapy. Acknowledging these 
limitations, no signiﬁ  cant diﬀ  erence has been detected in 
disease progression (modiﬁ   ed Stoke Ankylosing 
Spondylitis Spine Score) between patients with active AS 
treated with etanercept, adalimumab or inﬂ  iximab 
therapy compared with controls [34-36].
Treatment regimes and responsiveness
Currently it appears probable that most patients will 
require indeﬁ   nite treatment, although dropout-rate 
Table 3. Intention to treat data for infl  iximab, etanercept and adalimumab
    Week 0  Week 2  Week 6  Week 12  Week 24  Year 1  Year 2  Year 3
Disease  measure  Drug  (%) (%) (%) (%) (%) (%) (%) (%)
BASDAI 50  Infl  iximab [24,93-95]  0  41  ~58  53     47  41  47
  Etanercept  [25]  0    57  71         
  Adalimumab  [13]  0        43 51 56 59 
                   
ASAS  20  Infl   iximab  [37,71]  0  ~50 ~61 ~62 ~61     74 
  Etanercept  [96,97] 0 53   60  ~76    83 
  Adalimumab  [10,13]  0  ~42  ~56  58  65   65 
                   
ASAS  40  Infl   iximab  [93,95]  0     ~32 50  47 ~54 52  50
  Etanercept  [97]  0        49  ~64  ~62   ~66
  Adalimumab  [13] 0     ~35    46   51 
                   
ASAS  5/6  Infl   iximab  [93]  0     ~34  ~63  ~52 53 ~48 46
 Etanercepta  [98]  0     ~50 ~69 ~60  65    
  Adalimumab  [13]  0     ~37 48  59 ~55 59 
                   
ASAS Partial Remission  Infl  iximab [71]  0  ~10  ~17  ~21  22  ~23  ~29 
 Etanercepta  [98]  0     31  31 ~27 31    
  Adalimumab  [13] 0     ~20  21  24   34 
Intention-to-treat data from randomised control trials and open-label extensions based on duration of anti-TNF therapy for infl  iximab, etanercept and adalimumab. 
ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. aEtanercept ASAS 5/6 and partial remission 
intention-to-treat data are from patients recommencing etanercept after withdrawing for several months after a 6-month randomised control trial with etanercept.
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Stopping treatment appears to allow relapse in almost all 
patients [39] but most patients respond again on retreat-
ment.  Everyday clinical experience, however, indicates 
that some patients are able to withdraw treatment for 
periods of months and occasionally indeﬁ  nitely. Th  ere 
are few data to clarify the numbers of patients in whom 
drug-free remission may be expected or the charac-
teristics of patients in whom achievement of this is likely. 
Results of on-demand treatment led to results that were 
inferior to those of regular treatment [40].
Response to anti-TNF treatment in AS is greatest in 
patients with short-duration disease [23], high BASDAI 
and high acute phase markers, in particular C-reactive 
protein [41]. Biomarkers predictive of responsiveness to 
treatment or other outcomes have not clearly been 
identiﬁ   ed; serum levels of metalloproteinase-3 may 
predict radiographic progres  sion in AS [42]. Failure of 
the ﬁ  rst anti-TNF drug does not predict success or failure 
of switching to a second or third anti-TNF drug [43-45].
Peripheral spondyloarthritis
Few studies have focused speciﬁ   cally on these lesions 
within the context of SpA, the majority of studies of 
peripheral SpA addressing psoriatic arthritis (PsA). It is 
not clear to what extent data on this condition are 
applicable to the generalisation of peripheral SpA; nor is 
it clear whether data on small joint polyarthritis are 
applicable to large joint oligoarthritis. With these caveats, 
however, it is reasonable to summarise the position in 
PsA and the disparate data of other peripheral SpA 
lesions, with the expectation that many conclusions are 
broadly applicable to peripheral SpA with or without 
axial or other associated lesions.
Psoriatic arthritis
As in AS, the diﬃ   culties of developing robust diagnostic 
criteria and appropriate disease-speciﬁ  c  outcome 
measures have recently been partially overcome by the 
work of the Classiﬁ  cation of Psoriatic Arthritis CASPAR 
international study group and the Group for Research 
and Assessment of Psoriasis and Psoriatic Arthritis 
[46,47]. Th  e former has developed and validated a 
simpliﬁ  ed and highly speciﬁ  c set of diagnostic criteria 
that distinguishes PsA from non-PsA with a sensitivity 
and speciﬁ  city of 0.914 and 0.987, respectively [46]. Th  e 
Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis has also established evidence-based 
practice recommendations for treatment of PsA based on 
a systematic literature review of each manifestation along 
with a consensus opinion by both rheumatologists and 
dermatologists [48]. Pharmacological therapies include 
nonsteroidal anti-inﬂ   ammatory drugs, intraarticular 
steroids, DMARDs and biological therapies. In a 
meta-analysis of conventional DMARDs and anti-TNF 
agents in PsA, the three licensed TNF blocking drugs 
were found to have eﬃ     cacy/toxicity ratios that were 
superior to conventional DMARDs as either 
monotherapy or combination therapy [49]. Available data 
do not diﬀ  er  entiate between adalimumab, etanercept and 
inﬂ  iximab so far as eﬃ   cacy in PsA is concerned [50,51]. 
Each has demonstrated eﬃ     cacy in terms of disease 
activity and symptom control, health-related quality of 
life and function and modiﬁ  cation of disease progression. 
Table 4 presents a summary of the key outcomes for 
assessment of PsA.
Disease activity
Etanercept treatment has led to signiﬁ  cant improvement 
in both arthritis and skin symptoms in patients with PsA 
[52].  Further studies have shown that 60% of those 
receiving etanercept achieved an American College of 
Rheumatology (ACR) 20 response, with one-quarter of 
eligible patients achieving a 75% reduction in the 
Psoriasis Area and Severity Index (PASI). ACR 20 
criteria, Psoriatic Arthritis Response Criteria, and PASI 
50 criteria were met by 64%, 84%, and 62%, respectively, 
of patients receiving etanercept at the end of the 48-week 
open-label period [53].  Approximately 80% of patients 
meet Psoriatic Arthritis Response Criteria by 4 weeks, 
and substantial falls in the PASI are seen by 24 weeks of 
treatment.  Comparable ACR and Psoriatic Arthritis 
Response Criteria responses have also been demonstrated 
with inﬂ  iximab [54]  and adalimumab [55]. Comparable 
outcomes over 24 weeks have been reported recently 
with golimumab, with approximately 50% achieving ACR 
20 responses and concomitant improvements in PASI, 
nail involvement (NAPSI) and a PsA-modiﬁ  ed version of 
the Maastricht Ankylosing Spondylitis Enthesitis Scale 
(MASES) [56]. Although originally devised and validated 
for rheumatoid arthritis, the Disease Activity Score is also 
frequently used in the assessment of PsA – although this is 
inappropriate for patients with oligoarticular disease.
Data from the British Society for Rheumatology 
Biologics Register indicate that advancing age, female 
gender and corticosteroid therapy were associated with 
poorer clinical response rates [51].
Diff  ering treatment regimes
In clinical trials most data have been obtained from 
patients receiving TNF blockers and methotrexate in 
combination. It is  clear, however, that TNF blockade 
alone is eﬀ  ective treatment for PsA [57] and the place of 
monotherapy versus combination therapy for PsA has yet 
to be fully deﬁ  ned.
In observational studies, switching between the three 
licensed anti-TNF agents due to adverse events or loss of 
eﬃ   cacy has conferred improvement in clinical outcomes 
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larger trials are required to conﬁ  rm this eﬀ  ect [58].
Health-related quality of life and physical function
Improvement in physical disability, in terms of improve-
ment in the Health Assessment Questionnaire score, has 
been widely reported in response to anti-TNF therapies, 
although this is partially dependent upon the pre-
treatment state. Randomised control trial data for anti-
TNF agents conﬁ   rm improvement in the physical 
component of the SF-36 and Health Assessment 
Questionnaire [55,56,59] and the SF-36 mental compo-
nent with inﬂ  iximab [55,56,59]; these eﬀ  ects are main-
tained in follow-up trials for up to 2 years [60-62]. 
Adalimumab, etanercept and inﬂ   iximab are associated 
with similar responses in terms of quality of life (SF-36) 
and functional status (Health Assessment Questionnaire) 
in normal clinical practice [63].
Radiographic disease progression
Conventional DMARDs have not been shown to induce 
signiﬁ  cant inhibition of radiographic disease progression. 
In contrast, studies with adalimumab, etanercept and 
inﬂ   iximab have all demonstrated inhibition of radio-
logical progression as evidenced by plain radiography 
scoring. Mease and colleagues reported a greater 
inhibition of radiographic progression in etanercept 
therapy versus placebo therapy at 1 year, with a mean 
unit change in total sharp score of –0.03 and +1.00, 
respectively [53]. Patients completing 2 years of 
etanercept had a mean adjusted change in total Sharp 
score of –0.38 from baseline [64]. Equally eﬀ  ective 
inhibition of structural damage has been reported with 
inﬂ  iximab [65] and adalimumab [66] up to 2 years. It is 
not clear whether concomitant methotrexate enhances 
this eﬀ  ect or helps to maintain eﬃ   cacy.
Reactive arthritis
In spite of the concept that reactive arthritis is initiated 
and driven by persistent bacterial infection, evidence that 
this is so or that the course of the disease is inﬂ  uenced by 
antimicrobial treatment is limited and controversial. 
Studies of short-term and long-term antibiotic mono-
therapy have indicated both the presence and lack of 
clinical eﬃ   cacy [7]. Establishing or refuting a role for 
antibiotic treatment in reactive arthritis is hindered by 
the lack of a gold standard diagnostic test to identify a 
presumed causal microorganism(s) and to demonstrate 
its eradication by appropriate treatment. Evidence 
relating to persistent infection in reactive arthritis has 
focused principally on Chlamydia trachomatis and 
Chlamydia pneumoniae. Th   ese organisms are known to 
possess the property of persisting in synovial tissue in a 
metabolically active state. A recent randomised control 
trial of patients with chronic reactive arthritis and 
detectable chlamydial DNA in synovial biopsy or blood 
demonstrated signiﬁ  cantly greater clinical response and 
probability of eradication of chlamydial DNA amongst 
patients randomised to combination antibiotic treatment 
compared with placebo [67]. Further studies are required 
to establish the role of antibiotics in the treatment of 
reactive arthritis.
Anecdotal reports on the use of anti-TNF therapy in a 
few patients with severe, chronic reactive arthritis 
suggest value [68], although the possibility of persistence 
of viable microorganisms within the joint and elsewhere 
raises the prospect of potentially serious sepsis with 
increased morbidity.
Undiff  erentiated peripheral spondyloarthritis
Treatment of peripheral SpA is usually inﬂ  uenced  or 
constrained by the associated key SpA conditions, with 
the exception of undiﬀ   erentiated forms of peripheral 
Table 4. Key outcome measures in common use for assessment of psoriatic arthritis
Outcome Instrument  Main  components  Reference
Disease activity  Composite measures   
   ACR 20, 50,   Percentage improvement in tender and swollen joint counts in addition to   [116]
    70 response  improvement in three out of fi  ve measures: physician’s and patient’s assessment 
      of disease activity, patient’s assessment of pain, acute phase reactant, and 
    functional  questionnaire
   PsARC   Improvement by >1 point in both physician’s and patient’s assessment of disease   [117]
      activity in addition to >30% reduction in tender and swollen joint counts
  Skin disease   
   PASI 50, 75  Percentage improvement in severity and extent of skin involvement  [118]
  Minimal disease activity  Having fi  ve of the following seven criteria: tender joint count <1; swollen joint   [119]
    count <1; PASI <1 or body surface area <3; patient pain VAS <15; patient global 
    disease activity VAS <20; health assessment questionnaire <0.5; and tender 
    entheseal points <1
Radiograph scoring  Sharp score  Joint erosion + joint narrowing scores  [120]
ACR, American College of Rheumatology; PASI, Psoriasis Area and Severity Index; PsARC, Psoriatic Arthritis Response Criteria; VAS, visual analogue scale.
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arthritis are clear [69],  validated disease outcome 
measures for peripheral SpA are limited. It remains 
unclear whether treatment of SpA at an undiﬀ  erentiated 
stage inﬂ  uences the subsequent development of irrever-
sible diﬀ  erentiated disease.
Anti-TNF treatment is associated with substantial 
sustained reductions in tender and swollen peripheral 
joint counts [70,71], although longer-term outcome data 
on subsequent need for surgery are awaited. It may be 
reasonable to transfer conclusions drawn from studies in 
PsA (vide supra) to other forms of peripheral SpA but, in 
reality, much information is still missing. In particular, 
data on the eﬃ   cacy of TNF blockade with respect to 
rapidly progressive hip destruction, which is a key 
indicator of bad prognosis in SpA, would be of great 
value.
In clinical practice, large joint monoarthritis, especially 
of the knee, remains a challenging problem that may not 
respond well to either conventional or biologic therapy. 
Current guidelines do not recommend anti-TNF treat-
ment for monoarthritis as the potential value in this 
context is unknown. Anecdotal accounts of intraarticular 
instillation of TNF-blocking agents into the knee of 
patients with AS and refractory peripheral monoarthritis 
indicate short-term value only [72].
Enthesitis
Clinically relevant enthesitis lesions are common 
through  out SpA, with up to 50% of patients with AS 
experi  encing symptomatic enthesitis at some time 
[73,74]. For many, conservative measures are adequately 
eﬀ  ective although the small beneﬁ  t aﬀ  orded by sulpha-
salazine does not justify the side-eﬀ  ect proﬁ  le [75].
Evidence of eﬃ   cacy of biologic treatment of enthesitis 
has been obtained principally from observations of 
concomitant peripheral enthesis lesions during studies of 
AS or PsA, with no clear data on treatment of severe 
individual lesions such as Achilles’ tendonitis. Short-term 
randomised controlled trials of 12 and 24 weeks of 
treatment demonstrated signiﬁ   cant improvement in 
enthesitis [10,24]; and in the open-label Rhapsody trial of 
adalimumab treatment of AS, MASES scores were 
reduced from a mean of 5 at baseline to 1 at the 12th 
week: 122 of 173 patients had resolution of plantar 
fasciitis over the same time frame [70].
Uveitis
While topical corticosteroids and mydriatics remain the 
primary treatment of anterior uveitis, anti-TNF therapies 
may be of value in those with recurrent or especially 
severe episodes. Meta-analysis of the use of inﬂ  iximab 
and etanercept in treatment of AS showed that both 
agents signiﬁ  cantly reduced the frequency of episodes of 
uveitis compared with placebo therapy, conferring an 
incidence of anterior uveitis of 3.4/100 patient-years, 
7.9/100 patient-years and 15.6/100 patient-years, 
respectively [76]. Similarly, adalimumab treatment has 
also been associated with a reduced incidence of acute 
anterior uveitis from 15 to 7.4/100 patient-years [77].
Retrospective analysis of the use of adalimumab, 
etanercept and inﬂ  iximab in the treatment of spondylo-
arthritides indicated that etanercept treatment led to a 
smaller reduction of uveitis ﬂ   ares than the other two 
agents studied and, in addition, ﬂ  ares of uveitis have been 
reported in patients starting etanercept therapy. Data for 
newer anti-TNF agents are awaited. It is not clear to what 
extent TNF blockade is appropriate for treatment of 
isolated uveitis in patients without other SpA features.
Newer biologic agents
It is clear that the licensed TNF-blocking drugs provide 
substantial beneﬁ  t for many, but by no means all, patients 
and that newer anti-TNF drugs are likely to share class 
eﬀ  ects. A number of newer licensed biologic agents are 
also eﬀ  ective in improving recognised disease outcomes 
for joint disease and/or co-morbidities, although the 
range of clinical beneﬁ   ts seen thus far with anti-TNF 
drugs will be hard to match or exceed.
TNF-blocking drugs
Of the newer TNF-blocking agents,  golimumab –  a 
human anti-TNFα monoclonal antibody – has been 
shown to achieve ACR responses similar to those 
achieved with other TNF blockers in the treatment of 
people with PsA and is generally well tolerated [56]. 
Treatment is also associated with improvement in health-
related quality of life (SF-36) and function (Health 
Assessment Questionnaire). Eﬀ  ectiveness in short-term 
trials of treatment for AS has already been cited above. 
Information about the eﬃ   cacy of certolizumab pegol is 
awaited.
It is well recognised that new agents entering the ﬁ  eld 
face particular challenges as recruitment to clinical trials 
is increasingly likely to include subjects with milder, less 
typical or more resistant disease. In consequence, data 
should be compared with earlier anti-TNF studies with 
some caution.
Non-TNF-blocking agents
Ustekinumab, an anti IL-12/IL-23 monoclonal antibody, 
has been shown – in a placebo-controlled randomised 
study of 70 patients with PsA – to be associated with 
signiﬁ  cant improvement in ﬁ  ve out of seven of the ACR 
component scores at week 12 of therapy. Reductions in 
the C-reactive protein level and swollen joint count did 
not achieve signiﬁ   cance in the treatment arm  [78]. 
Ustekinumab has demonstrated eﬃ   cacy in most patients 
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IL-10 treatment showed some improvement in skin 
disease (PASI) but no improvement in measures of PsA 
in a small, double-blind, placebo-controlled study in 
patients with PsA [80]. Alefacept, a fully human fusion 
protein that inhibits leucocyte function by binding to 
CD2 on the surface of T cells, is an eﬀ  ective treatment of 
moderate to severe chronic plaque psoriasis [81]. In a 
recent study, combined with methotrexate, similar ACR 
and PASI responses to those obtained with anti-TNF 
treatment were demonstrated [82]. Th   e safety proﬁ  le also 
appears similar, so this agent appears promising for the 
treatment of both skin and musculoskeletal disease.
No randomised control trial data for abatacept or 
tocilizumab in the context of SpA have yet been reported.
Safety of biologic agents in spondyloarthritis
Th  e safety proﬁ   le of the widely used TNFα blocking 
agents has been extensively documented in the treatment 
of rheumatoid arthritis; safety data are also extensive in 
SpA but less complete. Long-term studies with 
inﬂ  iximab, etanercept and adalimumab in AS and PsA 
have revealed mostly mild to moderate adverse events, 
including upper respiratory tract infections, diarrhoea, 
headache and injection-site reactions [11-13,59,60,64,83]. 
A recent analysis of data from the British Society for 
Rheumatology Biologics Register has conﬁ  rmed  that 
TNFα blocking agents in PsA have a similar adverse 
event proﬁ  le and incidence of malignancy to DMARD 
therapy in seronegative arthritis [51]. Further studies of 
adequate statistical power and duration are required, 
however, before excluding a carcinogenic property of 
these drugs in SpA.
Other biologic agents have been less thoroughly 
evaluated. In the predominantly young SpA population, 
eﬀ   ects on cardiovascular risk and pregnancy are 
especially relevant. Accelerated atherosclerosis is likely to 
be the major contributor to increased standardised 
mortality rates seen in the spondyloarthritides. 
Provisional data from open-label studies have reported 
signiﬁ   cant amelioration of the proatherogenic lipid 
proﬁ   le and acute phase reactants of 92 patients with 
highly active AS after 3 months of etanercept [84], 
although it is not clear whether such changes will confer 
cardiovascular disease protection.
Use of any biologic drug in pregnancy is not supported. 
Data on fertility and teratogenicity have generally been 
drawn from non-SpA populations, although it is clear 
that foetal and maternal risks are small with TNF 
blockade treatment. Decisions about cessation or 
introduction of anti-TNF treatment in both men and 
women when pregnancy is desired or possible should be 
made on an individual basis taking into account known 
risks and maternal health [85].
Guidelines for treatment of spondyloarthritis with 
biologic agents
Guidance regarding the use of anti-TNF agents in the 
treatment of AS [26,86,87] and PsA [9,88-90] have been 
issued by several national and international agencies. 
Consensus on the classiﬁ  cation of pre-radiographic axial 
SpA [91] may lead to revised regulatory decisions on the 
use of TNF blockade treatment in early AS with 
radiographic changes.
Conclusion
It is clear that TNF blockade treatment exerts a profound 
beneﬁ  cial eﬀ  ect on symptoms in the majority of, but not 
all, patients with severe SpA. It is also clear that 
peripheral joint damage is signiﬁ   cantly reduced by 
treatment, although this appears not to be the case for 
spinal disease. Th   ere is thus a need both to establish the 
case for early treatment that will prevent, rather than 
minimise, joint damage and to understand the reasons 
for apparent lack of damage prevention in spondylitis.
Inevitably availability of biologic therapy is and will 
remain restricted on the bases of potential toxicity and 
cost. Th  us better targeting of treatment through use of 
clinical criteria and biomarkers is essential to ensure that 
only those who need them receive biologic drugs. Such 
need must be based both on the biology of the disease 
and on the life quality of the individual. Prevention of 
damage can surely underpin a better lifestyle and perhaps 
a longer life in good health. But attaining wellness even if 
some skeletal damage is done may well provide an equally 
strong and reasonable motive for use of biologic agents 
provided that the data to support this contention are 
robust and the criteria for improved quality of life are 
clearly established. In this context, enabling people with 
SpA to remain in work and maximise their individual 
productive potential must be seen as key elements for the 
eﬃ   cacy of treatment. Th  e balance point must be found 
between the social cost-beneﬁ  ts of  restoring people to 
good health and productive working lives and the 
substantial costs and risks of treatment.
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